Delivery Order SPE2DB25D3018-SPE2DB25FUXVE
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $12,497.80 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 11, 2025, with an ultimate completion date of August 12, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $32,318.92 firm fixed price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 1, 2025, with an ultimate completion date of August 4, 2025. This non-competitive delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be performed at...
- The Defense Logistics Agency awarded a delivery order valued at $6,223.32 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) effective July 31, 2025, with an ultimate completion date of August 1, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child award under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $9,728.70 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on August 28, 2025, with an ultimate completion date of August 29, 2025. This firm fixed-price delivery order represents a competitively awarded, non-set-aside contract with performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $30,927.58 to AmerisourceBergen Drug Corp for RINVOQ ER 15 MG tablets (30-count units) on July 28, 2025, with an ultimate completion date of July 29, 2025. This is a firm fixed-price, non-set-aside contract executed under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion global pharmaceutical support vehicle running through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a delivery order valued at approximately $40.2K to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on September 3, 2025, with completion scheduled for September 4, 2025. This firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (valued at $1 billion through December 2026), which serves as a comprehensive pharmaceutical supply vehicle...
- The Defense Logistics Agency awarded a delivery order valued at $12,990.98 to AmerisourceBergen Drug Corp for RINVOQ ER 15 MG tablets (30-count package) on September 4, 2025, with completion scheduled for September 5, 2025. This firm fixed-price delivery order represents a competitively awarded, non-set-aside contract with performance to be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award falls under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $11,859.53 to AmerisourceBergen Drug Corp on July 14, 2025, for RINVOQ ER 15 mg tablets (quantity: 30 units). This competitive award, using firm fixed price terms with no set-aside designation, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX). The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count unit dose) valued at $6,223.32 on September 19, 2025, with an ultimate completion date of September 22, 2025. This non-competitive, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The order will be fulfilled at the vendor's corporate headquarters in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $17,483.59 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-unit packaging) on July 14, 2025, with completion targeted for July 15, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion prime vendor agreement running through December 2026. The order will be fulfilled...
- SPE2DB25D3018Indefinite Delivery Contract
- SPE2DB25D3018-SPE2DB25FUXVEDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $24,397.55 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on June 26, 2025, with an ultimate completion date of June 27, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion comprehensive pharmaceutical supply vehicle running through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical federal vendor supplying medications, vaccines, medical devices, and specialized healthcare commodities to military and veteran healthcare systems. This delivery order for RINVOQ ER—a prescription medication used in the treatment of rheumatoid arthritis—exemplifies the company's role in supporting the Defense Health Agency and other government healthcare systems with pharmaceutical products across multiple therapeutic domains. The award reflects AmerisourceBergen's established capability to meet federal procurement requirements through competitive bidding and its extensive portfolio of pharmaceutical deliveries under the DLA's medical supply chain framework.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $24.4k | 6/26/25 |